EGFR and lung adenocarcinoma: The results showed that the IC50 of gefitinib or osimertinib decreased after MCAM knockdown in EGFR-TKI-resistant lung adenocarcinoma cells (Fig. 2C-D), indicating that the sensitivity to EGFR-TKIs was restored to a certain extent.